<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The CHA(2)DS(2)-VASc and CHADS(2) risk stratification schemes are used to predict <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> and <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> in patients with <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>However, limited data are available regarding the utility of these risk stratification schemes for <z:hpo ids='HP_0001297'>stroke</z:hpo> in patients with <z:hpo ids='HP_0004749'>atrial flutter</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>A retrospective analysis of 455 transesophageal echocardiographic studies in patients with <z:hpo ids='HP_0004749'>atrial flutter</z:hpo> was performed to identify left atrial (LA) <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> and/or spontaneous echocardiographic contrast (SEC) </plain></SENT>
<SENT sid="3" pm="."><plain>The CHA(2)DS(2)-VASc (<z:hpo ids='HP_0001635'>Congestive heart failure</z:hpo>, <z:hpo ids='HP_0000822'>Hypertension</z:hpo>, Age ≥75 years [doubled risk weight], <z:hpo ids='HP_0000819'>Diabetes mellitus</z:hpo>, previous <z:hpo ids='HP_0001297'>Stroke</z:hpo>/<z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo> [doubled risk weight], <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">Vascular disease</z:e>, Age 65 to 74 years, Sex) and CHADS(2) (<z:hpo ids='HP_0001635'>Congestive heart failure</z:hpo>, <z:hpo ids='HP_0000822'>Hypertension</z:hpo>, Age ≥75 years, <z:hpo ids='HP_0000819'>Diabetes mellitus</z:hpo>, previous <z:hpo ids='HP_0001297'>Stroke</z:hpo>/<z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo> [double risk weight]) scores were calculated to stratify the risk of <z:hpo ids='HP_0001297'>stroke</z:hpo> or transient cerebrovascular ischemic events </plain></SENT>
<SENT sid="4" pm="."><plain>Transesophageal echocardiography revealed LA <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> in 5.3% and SEC in 25.9% of patients </plain></SENT>
<SENT sid="5" pm="."><plain>Using CHADS(2), LA <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> was found in 2.2% of the low-intermediate-risk group and 8.3% of the high-risk group (p = 0.005) </plain></SENT>
<SENT sid="6" pm="."><plain>SEC was found in 19.8% of the low-intermediate-risk group and 32% of the high-risk group (p = 0.004) </plain></SENT>
<SENT sid="7" pm="."><plain>Using CHA(2)DS(2)-VASc, LA <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> was found in 1.7% of the low-intermediate-risk group and 6.5% of the high-risk group (p = 0.053) </plain></SENT>
<SENT sid="8" pm="."><plain>SEC was found in 11.8% of the low-intermediate-risk group versus 30.9% of the high-risk group (p = 0.004) </plain></SENT>
<SENT sid="9" pm="."><plain>The sensitivity for LA <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e>/SEC with a high CHADS(2) and CHA(2)DS(2)-VASc score was 64.8% and 88.7%, respectively (p = 0.0001) </plain></SENT>
<SENT sid="10" pm="."><plain>The specificity for LA <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e>/SEC with high CHADS(2) and CHA(2)DS(2)-VASc scores was 52.6% and 28.9%, respectively (p = 0.0001) </plain></SENT>
<SENT sid="11" pm="."><plain>In conclusion, both CHA(2)DS(2)-VASc and CHADS(2) scores are useful for <z:hpo ids='HP_0001297'>stroke</z:hpo> risk stratification in patients with <z:hpo ids='HP_0004749'>atrial flutter</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>CHA(2)DS(2)-VASc had greater sensitivity for LA <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> and SEC detection at the cost of reduced specificity </plain></SENT>
</text></document>